Paolo Tarantino: DB06 showed relevant activity with T-DXd for MBC

Paolo Tarantino shared a post on X:

“DB06 showed relevant activity with T-DXd for the 1L treatment of HER2-0 (ultralow) MBC.

What about in the pretreated setting? In our large RW analysis, after a median of 3 prior lines of treatment, T-DXd showed comparable rwPFS (median 6.3-7.8 months) in HER2-low and HER2-0 MBC.”

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.